Galera Therapeutics (GRTX) Competitors $0.02 0.00 (-9.00%) As of 09/19/2025 12:33 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock GRTX vs. OGEN, XBIO, CNSP, TCRT, ADTX, ONCO, APVO, GRI, INM, and CMNDShould you be buying Galera Therapeutics stock or one of its competitors? The main competitors of Galera Therapeutics include Oragenics (OGEN), Xenetic Biosciences (XBIO), CNS Pharmaceuticals (CNSP), Alaunos Therapeutics (TCRT), Aditxt (ADTX), Onconetix (ONCO), Aptevo Therapeutics (APVO), GRI Bio (GRI), InMed Pharmaceuticals (INM), and Clearmind Medicine (CMND). These companies are all part of the "pharmaceutical products" industry. Galera Therapeutics vs. Its Competitors Oragenics Xenetic Biosciences CNS Pharmaceuticals Alaunos Therapeutics Aditxt Onconetix Aptevo Therapeutics GRI Bio InMed Pharmaceuticals Clearmind Medicine Galera Therapeutics (NASDAQ:GRTX) and Oragenics (NYSE:OGEN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings. Which has preferable earnings and valuation, GRTX or OGEN? Galera Therapeutics is trading at a lower price-to-earnings ratio than Oragenics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalera TherapeuticsN/AN/A-$59.08M-$0.19-0.10OragenicsN/AN/A-$20.66M-$21.42-0.06 Does the media favor GRTX or OGEN? In the previous week, Galera Therapeutics' average media sentiment score of 0.00 equaled Oragenics'average media sentiment score. Company Overall Sentiment Galera Therapeutics Neutral Oragenics Neutral Do institutionals and insiders believe in GRTX or OGEN? 50.8% of Galera Therapeutics shares are held by institutional investors. Comparatively, 18.7% of Oragenics shares are held by institutional investors. 12.9% of Galera Therapeutics shares are held by insiders. Comparatively, 4.9% of Oragenics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is GRTX or OGEN more profitable? Galera Therapeutics' return on equity of 0.00% beat Oragenics' return on equity.Company Net Margins Return on Equity Return on Assets Galera TherapeuticsN/A N/A -99.34% Oragenics N/A -2,087.95%-486.56% Which has more risk and volatility, GRTX or OGEN? Galera Therapeutics has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500. Comparatively, Oragenics has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. SummaryGalera Therapeutics beats Oragenics on 7 of the 8 factors compared between the two stocks. Get Galera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRTX vs. The Competition Export to ExcelMetricGalera TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.37M$858.70M$5.79B$10.40BDividend YieldN/A4.84%5.63%4.60%P/E Ratio-0.051.2176.4826.75Price / SalesN/A26.44531.72124.23Price / CashN/A19.5637.9261.55Price / Book-0.016.7013.726.40Net Income-$59.08M-$4.03M$3.29B$271.62M7 Day PerformanceN/A-1.27%2.65%3.46%1 Month PerformanceN/A7.66%6.01%9.87%1 Year PerformanceN/A16.40%80.02%28.45% Galera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRTXGalera TherapeuticsN/A$0.02-9.0%N/A-77.0%$1.37MN/A-0.0530Gap DownOGENOragenics0.0576 of 5 stars$1.30+2.4%N/A-91.7%$5.37MN/A-0.185XBIOXenetic Biosciences0.5474 of 5 stars$3.23-6.9%N/A-16.5%$5.36M$2.50M-1.624Positive NewsCNSPCNS Pharmaceuticals1.6188 of 5 stars$9.14-0.7%$20.00+118.8%-91.2%$5.29MN/A0.005High Trading VolumeTCRTAlaunos Therapeutics0.3888 of 5 stars$2.36+4.7%N/A-14.2%$4.96M$10K-0.9640Positive NewsGap UpADTXAditxtN/A$1.04+4.8%N/A-100.0%$4.94M$130K0.0060ONCOOnconetix0.3201 of 5 stars$3.27+5.5%N/A-99.2%$4.79M$2.52M0.0012APVOAptevo Therapeutics3.1669 of 5 stars$1.50+4.2%$219,040.00+14,602,566.7%-100.0%$4.73M$3.11M0.0050Analyst UpgradeAnalyst RevisionGap UpHigh Trading VolumeGRIGRI Bio2.4026 of 5 stars$1.93+3.8%$22.00+1,039.9%-76.9%$4.68MN/A-0.171Gap UpINMInMed Pharmaceuticals0.9786 of 5 stars$2.32+4.5%N/A-58.1%$4.44M$4.60M-0.1910Positive NewsUpcoming EarningsHigh Trading VolumeCMNDClearmind Medicine0.6116 of 5 stars$1.01-1.6%N/A-7.8%$4.38MN/A-1.33N/ANews CoveragePositive News Related Companies and Tools Related Companies OGEN Competitors XBIO Competitors CNSP Competitors TCRT Competitors ADTX Competitors ONCO Competitors APVO Competitors GRI Competitors INM Competitors CMND Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRTX) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GRTX Stock Alerts